Cytarabine Archives - Medical Conferences

No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics

Presented By

Prof. Nigel Russell, Guy's and St Thomas' NHS Foundation Trust, UK

Trial

Phase 3, AML19

Conference

EHA 2022

Type

News article

1 July 2022 11:49

Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients

Presented By

Dr Justin Grenet, Weill Cornell Medical Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:51

Encouraging results of novel triplet combination for AML

Presented By

Dr Patrick Reville, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:48

Reduced-intensity conditioning ASCT is effective in older patients with AML

Presented By

Prof. Nigel Russell, Guy's Hospital, UK

Trial

AML16; AML18

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:55

MATRix with ASCT: best long-term survival for primary CNS lymphoma

Presented By

Dr Gerald Illerhaus, Klinikum der Landeshauptstadt Stuttgart, Germany

Trial

Phase 2, IELSG32

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 12:05

OS benefit in VIALE-C trial

Presented By

Prof. Andrew Wei, Monash University, Australia

Trial

Phase 3, VIALE-C

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:22

Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT

Presented By

Dr Xiaowen Tang; Dr James Foran

Trial

Phase 2, ECOG-ACRIN E2906

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 13:16